RetaMaps

Ameri-Cal Weight Clinic

Ameri-Cal Weight Clinic · 39470 Paseo Padre Parkway · Fremont, CA 94538

5.0· 2 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss

About this practice

Ameri-Cal Weight Clinic in Fremont, California, is a medically supervised outpatient weight-loss clinic that, per its website, is supported by a bariatric doctor and references serving patients since 2000. Its listing shows semaglutide, tirzepatide, hormone care, aesthetics and telehealth. Google shows a 5.0-star rating from 2 reviews, the earliest in 2018 and none in the past year, so review data for this office is limited.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayYes
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 2 reviews

Counts computed by RetaMaps from public Google reviews; most recent review 2025-04-22. Read the reviews themselves on the practice's Google listing.

What patients say

This practice holds a ★5.0 Google rating across 2 reviews. 100% of the 2 reviews we analyzed are 5-star. reviewers most often mention staff & front desk (1).

5★
2
4★
0
3★
0
2★
0
1★
0

Most recent Google reviews

Jason B.★★★★★2025-04-22

Extremely friendly team - clear communication and very efficient.

Reviews and counts are from this practice's public Google Business listing and reflect their authors' opinions, not RetaMaps'. See all reviews on Google.

Nearby providers in Fremont

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs